Shasun Pharmaceuticals Limited Corporate Filings & Announcements

Latest corporate announcements and filings from Shasun Pharmaceuticals Limited on BSE

Search Inside the pdf :

18 Nov 2015

Company Update

Updates

BSE India

With reference to the earlier letter dated November 17, 2015 regarding the fire accident in one of the manufacturing blocks of the Company's Cuddalore API facility, Shasun Pharmaceuticals Ltd has now informed BSE that the Company have temporarily suspended the production, as directed by the Government authorities. The Company is working with the Government authorities to resume operations at the earliest....

Shasun Pharmaceuticals Limited

17 Nov 2015

Company Update

Updates

BSE India

Shasun Pharmaceuticals Ltd has informed BSE that:"We would like to inform you that there was a fire accident at New production block during trial & commissioning in Cuddalore API facility around 11.30 p.m on 16th November, 2015. We regret to inform the sad demise of one worker in the accident. One more injured employee has been admitted in the hospital for treatment. The company has informed the government authorities about the same and investigating the root cause of the accident....

Shasun Pharmaceuticals Limited

16 Nov 2015

Company Update

Shasun Pharmaceuticals receives USFDA approval for Carisoprodol Tablets

BSE India

Shasun Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 16, 2015 titled "Shasun Pharmaceuticals receives USFDA approval for Carisoprodol Tablets".

pdf

Shasun Pharmaceuticals Limited

06 Nov 2015

Corp. Action

Record Date for Scheme of Amalgamation

BSE India

Strides Arcolab Ltd has informed BSE that as approved by the Board of Directors of Strides Arcolab Ltd by a resolution passed on November 05, 2015, November 19, 2015 shall be the Record Date fixed for the purpose of determining the names of the shareholders of Shasun Pharmaceuticals Ltd who shall be entitled to shares in Strides Arcolab Ltd (as consideration under the Scheme of Amalgamation), in the exchange ratio of 5 (five) equity shares of Rs....

pdf

Shasun Pharmaceuticals Limited

27 Oct 2015

Result

Financial Results with Results Press Release & Limited Review Report for Sept 30, 2015

BSE India

Shasun Pharmaceuticals Ltd has informed BSE about the Financial Results, Results Press Release & a copy of the Limited Review Report for the period ended September 30, 2015.

pdf

Shasun Pharmaceuticals Limited

19 Oct 2015

SAST

Board Intimation for Results & Closure of Trading Window

BSE India

Shasun Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to the held on October 27, 2015, inter alia, to consider the Unaudited Financial Results for the quarter ended September 30, 2015.Further as per the provisions of the Company's Code for Prevention of Insider Trading, the trading window for designated employees of the Company closed from September 10, 2015 to October 29, 2015 (both days inclusive).

Shasun Pharmaceuticals Limited

13 Oct 2015

Board Meeting

Outcome of Board Meeting

BSE India

Shasun Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 13, 2015, allotted 31,600 equity shares of the face value of Rs. 2 each under the ESOP Scheme.The paid up share capital of the Company has increased from Rs. 13,44,47,704/- consisting of 6,72,23,852 equity shares to Rs. 13,45,10,904/- consisting of 6,72,55,452 equity shares.

Shasun Pharmaceuticals Limited

13 Oct 2015

Company Update

Shareholding Pattern for September 30, 2015

BSE India

Shasun Pharmaceuticals Ltd has informed BSE about the Shareholding Pattern as on September 30, 2015.

pdf

Shasun Pharmaceuticals Limited

29 Sep 2015

SAST

Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

BSE India

S Vimal Kumar & V Leela has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE

pdf

Shasun Pharmaceuticals Limited

29 Sep 2015

SAST

Revsied Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

BSE India

Shasun Pharmaceuticals Ltd has mow submitted the revsied disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE

pdf

Is Shasun Pharmaceuticals Limited worth buying?

8 Votes:

Buy 62.5%

Sell 25.0%

Hold 12.5%